MedPath

Brachytherapy in Treating Patients With Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Registration Number
NCT00003312
Lead Sponsor
Radiation Therapy Oncology Group
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of brachytherapy in treating patients with stage I or stage II prostate cancer.

Detailed Description

OBJECTIVES: I. Evaluate the effectiveness of transrectal ultrasound guided permanent radioactive implantation of the prostate in patients with confined adenocarcinoma of the prostate. II. Assess the overall survival, disease specific survival, clinical relapse (local or distant), PSA levels, and genitourinary and gastrointestinal morbidity in these implant patients. III. Assess the quality of life of these patients.

OUTLINE: This is a multicenter study. Patients receive transrectal ultrasound guided radioactive I-125 seeds implanted into the prostate. At least one week prior to implant, patients undergo transurethral ultrasound study to determine the volume of prostate. Following implantation, seeds that have extruded into the bladder or lodged in the urethral wall are retrieved, and extra seeds may be implanted into identified "cold spots" for uniform seed distribution. Prostate rebiopsy is required before starting hormonal therapy for local progression or biochemical failure without clear focus of progression. Quality of life is assessed every 3 months for 1 year, then every 6 months for 1 year, and then annually for 3 years. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 95 patients will be accrued for this study within 1 year.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
95
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (258)

Veterans Affairs Medical Center - Birmingham

🇺🇸

Birmingham, Alabama, United States

University of Alabama Comprehensive Cancer Center

🇺🇸

Birmingham, Alabama, United States

Huntsville Hospital System

🇺🇸

Huntsville, Alabama, United States

Urology Associates - Mobile AL

🇺🇸

Mobile, Alabama, United States

MBCCOP - University of South Alabama

🇺🇸

Mobile, Alabama, United States

Alabama Oncology, LLC

🇺🇸

Montgomery, Alabama, United States

Radiation Oncology Associates of West Alabama

🇺🇸

Tuscallosa, Alabama, United States

Providence Cancer Therapy Center

🇺🇸

Anchorage, Alaska, United States

St. Joseph's Hospital and Medical Center

🇺🇸

Phoenix, Arizona, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Scroll for more (248 remaining)
Veterans Affairs Medical Center - Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.